Maryland 2025 Regular Session

Maryland House Bill HB813 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3	3		EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
4	4		[Brackets] indicate matter deleted from existing law.
5	5		Underlining indicates amendments to bill.
6	6		Strike out indicates matter stricken from the bill by amendment or deleted from the law by
7	7		amendment.
8		-	Italics indicate opposite chamber/conference committee amendments.
9	8		hb0813
10	9
11	10		HOUSE BILL 813
12		-	J5 EMERGENCY BILL (5lr2785)
13		-	ENROLLED BILL
14		-	— Health and Government Operations/Finance —
15		-	Introduced by Delegates S. Johnson and A. Johnson, A. Johnson, Alston, Bagnall,
16		-	Bhandari, Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez,
17		-	Martinez, M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga,
18		-	Taveras, White Holland, Woods, and Woorman
19		-
20		-	Read and Examined by Proofreaders:
21		-
22		-	_______________________________________________
23		-	Proofreader.
24		-	_______________________________________________
25		-	Proofreader.
26		-
27		-	Sealed with the Great Seal and presented to the Governor, for his approval this
28		-
29		-	_______ day of _______________ at _________________ _______ o’clock, ________M.
30		-
31		-	______________________________________________
32		-	Speaker.
	11	+	J5 EMERGENCY BILL 5lr2785
	12	+	HB 880/24 – HGO CF SB 438
	13	+	By: Delegates S. Johnson and A. Johnson, A. Johnson, Alston, Bagnall, Bhandari,
	14	+	Cullison, Guzzone, Hill, Hutchinson, Kaiser, Kerr, Kipke, Lopez, Martinez,
	15	+	M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Ross, Szeliga, Taveras,
	16	+	White Holland, Woods, and Woorman
	17	+	Introduced and read first time: January 29, 2025
	18	+	Assigned to: Health and Government Operations
	19	+	Committee Report: Favorable with amendments
	20	+	House action: Adopted
	21	+	Read second time: March 1, 2025
33	22
34	23		CHAPTER ______
35	24
36	25		AN ACT concerning 1
37	26
38	27		Pharmacy Benefits Administration – Maryland Medical Assistance Program and 2
39	28		Pharmacy Benefits Managers 3
40	29		Maryland Insurance Administration and Maryland Department of Health – 4
41	30		Workgroup to Study Pharmacy Benefits Managers 5
42	31
43	32		FOR the purpose of altering the reimbursement levels for drug products that the Maryland 6
44	33		Medical Assistance Program is required to establish and that pharmacy benefits 7
45	34		managers that contract with a pharmacy on behalf of a managed care organization 8
46	35		are required to reimburse the pharmacy; altering the definition of “purchaser” for 9
47	36		purposes of certain provisions of law regulating pharmacy benefits managers to 10
48	37		include certain insurers, nonprofit health service plans, and health maintenance 11
49		-	organizations requiring the Maryland Insurance Administration and the Maryland 12 2 HOUSE BILL 813
	38	+	organizations requiring the Maryland Insurance Administration and the Maryland 12
	39	+	Department of Health to convene a workgroup to study certain issues related to 13
	40	+	pharmacy benefits managers and report to certain committees on or before a certain 14
	41	+	date; and generally relating to pharmacy benefits administration a workgroup to 15
	42	+	study pharmacy benefits managers. 16
50	43
51		-
52		-	Department of Health, in consultation with the Prescription Drug Affordability 1
53		-	Board, to convene a workgroup to study certain issues related to pharmacy benefits 2
54		-	managers and report to certain committees on or before a certain date; and generally 3
55		-	relating to pharmacy benefits administration a workgroup to study pharmacy 4
56		-	benefits managers. 5
57		-
58		-	BY repealing and reenacting, with amendments, 6
59		-	Article – Health – General 7
60		-	Section 15–118(b) 8
61		-	Annotated Code of Maryland 9
62		-	(2023 Replacement Volume and 2024 Supplement) 10
63		-
64		-	BY adding to 11
65		-	Article – Health – General 12
66		-	Section 15–118(f) 13
67		-	Annotated Code of Maryland 14
68		-	(2023 Replacement Volume and 2024 Supplement) 15
69		-
70		-	BY repealing and reenacting, with amendments, 16
71		-	Article – Insurance 17
72		-	Section 15–1601(s) 18
73		-	Annotated Code of Maryland 19
74		-	(2017 Replacement Volume and 2024 Supplement) 20
75		-
76		-	BY adding to 21
77		-	Article – Insurance 22
78		-	Section 15–1632 23
79		-	Annotated Code of Maryland 24
80		-	(2017 Replacement Volume and 2024 Supplement) 25
81		-
82		-	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 26
83		-	That the Laws of Maryland read as follows: 27
84		-
85		-	Article – Health – General 28
86		-
87		-	15–118. 29
88		-
89		-	(b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION A ND 30
90		-	EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall 31
91		-	establish [maximum] MINIMUM reimbursement levels for the drug products for which 32
92		-	there is a generic equivalent authorized under § 12–504 of the Health Occupations Article[, 33
93		-	based on the cost of the generic product]. 34
94		-
95		-	(2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION , 35
96		-	MINIMUM REIMBURSEMEN T LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS 36
97		-	SUBSECTION SHALL BE AT LEAST EQUAL TO TH E NATIONAL AVERAGE DRUG 37 HOUSE BILL 813 3
98		-
99		-
100		-	ACQUISITION COST OF THE GENERIC P RODUCT PLUS THE FEE –FOR–SERVICE 1
101		-	PROFESSIONAL DISPENS ING FEE DETERMINED B Y THE DEPARTMENT IN 2
102		-	ACCORDANCE WITH THE MOST RECENT IN –STATE COST–OF–DISPENSING SURVEY . 3
103		-
104		-	[(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS 4
105		-	SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level 5
106		-	shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the 6
107		-	brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE 7
108		-	DETERMINED BY THE DEPARTMENT IN ACCORDA NCE WITH THE MOST RE CENT 8
109		-	IN–STATE COST–OF–DISPENSING SURVEY . 9
110		-
111		-	(4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION D O NOT APPLY TO: 10
112		-
113		-	(I) A PHARMACY OWNED BY OR UNDER THE SAME CORPO RATE 11
114		-	AFFILIATION AS A PHA RMACY BENEFI TS MANAGER; OR 12
115		-
116		-	(II) A MAIL ORDER PHARMACY . 13
117		-
118		-	(F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO 14
119		-	A MANAGED CARE ORGAN IZATION THAT USES A PHARMACY BENEFITS MA NAGER TO 15
120		-	MANAGE PRESCRIPTION DRUG COVERAGE BENEFI TS ON BEHALF OF THE MANAGED 16
121		-	CARE ORGANIZATION . 17
122		-
123		-	Article – Insurance 18
124		-
125		-	15–1601. 19
126		-
127		-	(s) (1) “Purchaser” means a person that offers a plan or program in the State, 20
128		-	including the State Employee and Retiree Health and Welfare Benefits Program, AN 21
129		-	INSURER, A NONPROFIT HEALTH S ERVICE PLAN , OR A HEALTH MAINTENANCE 22
130		-	ORGANIZATION , that: 23
131		-
132		-	[(1)] (I) provides prescription drug coverage or benefits in the State; and 24
133		-
134		-	[(2)] (II) enters into an agreement with a pharmacy benefits manager for 25
135		-	the provision of pharmacy benefits management services. 26
136		-
137		-	(2) “PURCHASER” DOES NOT INCLUDE A N ONPROFIT HEALTH 27
138		-	MAINTENANCE ORGANIZA TION THAT: 28
139		-
140		-	(I) OPERATES AS A GROUP MODEL; 29
141		-
142		-	(II) PROVIDES SERVICES SO LELY TO A MEMBER OR PATIENT OF 30
143		-	THE NONPROFIT HEALTH MAINTENANCE ORGANIZA TION; AND 31 4 HOUSE BILL 813
	44	+	BY repealing and reenacting, with amendments, 17
	45	+	Article – Health – General 18
	46	+	Section 15–118(b) 19
	47	+	Annotated Code of Maryland 20
	48	+	(2023 Replacement Volume and 2024 Supplement) 21 2 HOUSE BILL 813
144	49
145	50
146	51
147		-	(III) FURNISHES SERVICES THROUGH THE INTERNAL PHARMACY 1
148		-	OPERATIONS OF THE NO NPROFIT HEALTH MAINT ENANCE ORGANIZATION . 2
	52	+	BY adding to 1
	53	+	Article – Health – General 2
	54	+	Section 15–118(f) 3
	55	+	Annotated Code of Maryland 4
	56	+	(2023 Replacement Volume and 2024 Supplement) 5
149	57
150		-	15–1632. 3
	58	+	BY repealing and reenacting, with amendments, 6
	59	+	Article – Insurance 7
	60	+	Section 15–1601(s) 8
	61	+	Annotated Code of Maryland 9
	62	+	(2017 Replacement Volume and 2024 Supplement) 10
151	63
152		-	A PHARMACY BENEFITS MA NAGER THAT CONTRACTS WITH A PHARMACY ON 4
153		-	BEHALF OF A MANAGED CARE ORGANIZATION , AS DEFINED IN § 15–101 OF THE 5
154		-	HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT 6
155		-	THAT IS AT LEAST EQU AL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST 7
156		-	PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETER MINED BY THE 8
157		-	MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE 9
158		-	PROGRAM IN ACCORDANCE WITH T HE MOST RECENT IN –STATE 10
159		-	COST–OF–DISPENSING SURVEY . 11
	64	+	BY adding to 11
	65	+	Article – Insurance 12
	66	+	Section 15–1632 13
	67	+	Annotated Code of Maryland 14
	68	+	(2017 Replacement Volume and 2024 Supplement) 15
160	69
161		-	SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency 12
162		-	measure, is necessary for the immediate preservation of the public health or safety, has 13
163		-	been passed by a yea and nay vote supported by three–fifths of all the members elected to 14
164		-	each of the two Houses of the General Assembly, and shall take effect from the date it is 15
165		-	enacted. 16
	70	+	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 16
	71	+	That the Laws of Maryland read as follows: 17
166	72
167		-	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 17
168		-	That the Maryland Insurance Administration and the Maryland Department of Health, in 18
169		-	consultation with the Prescription Drug Affordability Board, shall: 19
	73	+	Article – Health – General 18
170	74
171		-	(1) convene a workgroup of interested stakeholders, including community 20
172		-	pharmacies from both chain and independent settings, pharmacy services administrative 21
173		-	organizations, health insurance carriers, plan sponsor representatives, drug wholesalers 22
174		-	and distributors, non–pharmacy benefit manager–owned mail order pharmacies, brand 23
175		-	name and generic drug manufacturers, pharmacists, pharmacy benefits managers, and 24
176		-	managed care organizations, and third–party experts in the field of drug pricing in 25
177		-	Medicaid; 26
	75	+	15–118. 19
178	76
179		-	(2) review reimbursement for pharmacists, including: 27
	77	+	(b) (1) [Except] SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION A ND 20
	78	+	EXCEPT as provided under paragraph [(2)] (3) of this subsection, the Program shall 21
	79	+	establish [maximum] MINIMUM reimbursement levels for the drug products for which 22
	80	+	there is a generic equivalent authorized under § 12–504 of the Health Occupations Article[, 23
	81	+	based on the cost of the generic product]. 24
180	82
181		-	(i) existing Maryland Medical Assistance Program requirements for 28
182		-	pharmacy benefits managers and managed care organizations related to dispensing fee 29
183		-	reimbursement, pharmacy benefits managers fees charged to pharmacies and the 30
184		-	Maryland Medical Assistance Program, transparency in pricing and reimbursement data, 31
185		-	specialty drug designations, and appeals processes; 32
	83	+	(2) EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS SUBSECTION , 25
	84	+	MINIMUM REIMBURSEMEN T LEVELS ESTABLISHED UNDER PARAGRAPH (1) OF THIS 26
	85	+	SUBSECTION SHALL BE AT LEAST EQUAL TO TH E NATIONAL AVERAGE DRUG 27
	86	+	ACQUISITION COST OF THE GENERIC PRODU CT PLUS THE FEE –FOR–SERVICE 28
	87	+	PROFESSIONAL DISPENS ING FEE DETERMINED B Y THE DEPARTMENT IN 29
	88	+	ACCORDANCE WITH THE MOST RECENT IN –STATE COST–OF–DISPENSING SURVEY . 30
186	89
187		-	(ii) how other states’ pharmacy benefits services operate in 33
188		-	Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia; 34
	90	+	[(2)] (3) [If] EXCEPT AS PROVIDED IN PARAGRAPH (4) OF THIS 31
	91	+	SUBSECTION, IF a prescriber directs a specific brand name drug, the reimbursement level 32
	92	+	shall be based on the [cost] NATIONAL AVERAGE DRUG ACQUISITION COST of the 33
	93	+	brand name product PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE 34
	94	+	DETERMINED BY THE DEPARTMENT IN ACC ORDANCE WITH THE MOS T RECENT 35
	95	+	IN–STATE COST–OF–DISPENSING SURVEY . 36
	96	+	HOUSE BILL 813 3
	97	+
	98	+
	99	+	(4) PARAGRAPHS (2) AND (3) OF THIS SUBSECTION D O NOT APPLY TO: 1
	100	+
	101	+	(I) A PHARMACY OWNED BY OR UNDER THE SAME CORPO RATE 2
	102	+	AFFILIATION AS A PHA RMACY BENEFITS MANAG ER; OR 3
	103	+
	104	+	(II) A MAIL ORDER PHARMACY. 4
	105	+
	106	+	(F) THE PROVISIONS OF § 15–1632 OF THE INSURANCE ARTICLE APPLY TO 5
	107	+	A MANAGED CARE ORGAN IZATION THAT USES A PHARMACY BENEFITS MA NAGER TO 6
	108	+	MANAGE PRESCRIPTION DRUG COVERAGE BENEFI TS ON BEHALF OF THE MANAGED 7
	109	+	CARE ORGANIZATION . 8
	110	+
	111	+	Article – Insurance 9
	112	+
	113	+	15–1601. 10
	114	+
	115	+	(s) (1) “Purchaser” means a person that offers a plan or program in the State, 11
	116	+	including the State Employee and Retiree Health and Welfare Benefits Program, AN 12
	117	+	INSURER, A NONPROFIT HEALTH S ERVICE PLAN , OR A HEALTH MAINTENA NCE 13
	118	+	ORGANIZATION , that: 14
	119	+
	120	+	[(1)] (I) provides prescription drug coverage or benefits in the State; and 15
	121	+
	122	+	[(2)] (II) enters into an agreement with a pharmacy benefits manager for 16
	123	+	the provision of pharmacy benefits management services. 17
	124	+
	125	+	(2) “PURCHASER” DOES NOT INCLUDE A NONPROFIT HEALTH 18
	126	+	MAINTENANCE ORGANIZA TION THAT: 19
	127	+
	128	+	(I) OPERATES AS A GROUP MODEL; 20
	129	+
	130	+	(II) PROVIDES SERVICES SO LELY TO A MEMBER OR PATIENT OF 21
	131	+	THE NONPROFIT HEALTH MAINTENANCE ORGANIZA TION; AND 22
	132	+
	133	+	(III) FURNISHES SERVICES T HROUGH THE INTERNAL PHARMACY 23
	134	+	OPERATIONS OF THE NO NPROFIT HEALTH MAINT ENANCE ORGANIZATION . 24
	135	+
	136	+	15–1632. 25
	137	+
	138	+	A PHARMACY BENEFITS MA NAGER THAT CONTRACTS WITH A PHARMACY ON 26
	139	+	BEHALF OF A MANAGED CARE ORGANIZATION , AS DEFINED IN § 15–101 OF THE 27
	140	+	HEALTH – GENERAL ARTICLE, SHALL REIMBURSE THE PHARMACY AN AMOUNT 28
	141	+	THAT IS AT LEAST EQU AL TO THE NATIONAL AVERAGE DRUG ACQUISITION COST 29
	142	+	PLUS THE FEE–FOR–SERVICE PROFESSIONAL DISPENSING FEE DETER MINED BY THE 30
	143	+	MARYLAND DEPARTMENT OF HEALTH FOR THE MARYLAND MEDICAL ASSISTANCE 31 4 HOUSE BILL 813
	144	+
	145	+
	146	+	PROGRAM IN ACCORDANCE WITH THE MOST RECENT IN –STATE 1
	147	+	COST–OF–DISPENSING SURVEY . 2
	148	+
	149	+	SECTION 2. AND BE IT FURTHER ENACTED, That this Act is an emergency 3
	150	+	measure, is necessary for the immediate preservation of the public health or safety, has 4
	151	+	been passed by a yea and nay vote supported by three–fifths of all the members elected to 5
	152	+	each of the two Houses of the General Assembly, and shall take effect from the date it is 6
	153	+	enacted. 7
	154	+
	155	+	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 8
	156	+	That the Maryland Insurance Administration and the Maryland Department of Health 9
	157	+	shall: 10
	158	+
	159	+	(1) convene a workgroup of interested stakeholders, including community 11
	160	+	pharmacies from both chain and independent settings, pharmacy services administrative 12
	161	+	organizations, pharmacists, pharmacy benefits managers, and managed care organizations 13
	162	+	and third–party experts in the field of drug pricing in Medicaid; 14
	163	+
	164	+	(2) review reimbursement for pharmacists, including: 15
	165	+
	166	+	(i) existing Maryland Medical Assistance Program requirements for 16
	167	+	pharmacy benefits managers and managed care organizations related to dispensing fee 17
	168	+	reimbursement, pharmacy benefits managers fees charged to pharmacies and the 18
	169	+	Maryland Medical Assistance Program, transparency in pricing and reimbursement data, 19
	170	+	specialty drug designations, and appeals processes; 20
	171	+
	172	+	(ii) how other states’ pharmacy benefits services operate in 21
	173	+	Medicaid, including in Ohio, Kentucky, New York, California, and West Virginia; 22
	174	+
	175	+	(iii) measures that offset the Department’s costs to fund the Medicaid 23
	176	+	Managed Care Program and adop t NADAC plus the Fee–for–Service Professional 24
	177	+	Dispensing, including: 25
	178	+
	179	+	1. savings associated with NADAC ingredient cost pricing 26
	180	+	and managed care organizations; and 27
	181	+
	182	+	2. pharmacy benefits managers administrative fee 28
	183	+	consolidation and rebate allocations; and 29
	184	+
	185	+	(iv) strategies for adopting pharmacy reimbursement parity and 30
	186	+	drug pricing transparency; 31
	187	+
	188	+	(3) review coverage requirements for specialty drugs, including: 32
	189	+
	190	+	(i) which drugs are considered specialty for purposes of formularies 33
	191	+	across carriers and pharmacy benefits managers; and 34
189	192		HOUSE BILL 813 5
190	193
191	194
192		-	(iii) measures that offset the Department’s costs to fund the Medicaid 1
193		-	Managed Care Program and adopt NADAC plus the Fee –for–Service Professional 2
194		-	Dispensing, including: 3
	195	+	(ii) what these drugs have in common for purposes of developing a 1
	196	+	new definition for “specialty drug”; 2
195	197
196		-	~~1. savings associated with NADAC ingredient cost pricing 4~~
197		-	~~and managed care organizations; and 5~~
	198	+	(4) review ERISA exemptions for pharmacy benefits management 3
	199	+	regulation, including: 4
198	200
199		-	2. ~~pharmacy benefits managers administrative fee 6~~
200		-	~~consolidation~~ and ~~rebate allocations;~~ and 7
	201	+	(i) the scope of Rutledge v. Pharmaceutical Care Management 5
	202	+	Association and subsequent case law and federal guidance; 6
201	203
202		-	(iv) strategies for adopting pharmacy reimbursement parity and 8
203		-	drug pricing transparency; 9
	204	+	(ii) how other states have responded to the Rutledge decision; and 7
204	205
205		-	(3) ~~review coverage requirements for specialty drugs~~, ~~including: 10~~
	206	+	(iii) what, if any, other State laws should be amended; 8
206	207
207		-	(i) which drugs are considered specialty for purposes of formularies 11
208		-	across carriers and pharmacy benefits managers; and 12
	208	+	(5) on or before December 31, 2025, submit an interim report on their 9
	209	+	findings and recommendations to the Senate Finance Committee and the House Health 10
	210	+	and Government Operations Committee, in accordance with § 2 –1257 of the State 11
	211	+	Government Article; and 12
209	212
210		-	(ii) what these drugs have in common for purposes of developing a 13
211		-	new definition for “specialty drug”; 14
	213	+	(6) on or before December 31, 2026, submit a final report on their findings 13
	214	+	and recommendations to the Senate Finance Committee and the House Health and 14
	215	+	Government Operations Committee, in accordance with § 2–1257 of the State Government 15
	216	+	Article. 16
212	217
213		-	(4) review ERISA exemptions for pharmacy benefits management 15
214		-	regulation, including: 16
215		-
216		-	(i) the scope of Rutledge v. Pharmaceutical Care Management 17
217		-	Association and subsequent case law and federal guidance; 18
218		-
219		-	(ii) how other states have responded to the Rutledge decision; and 19
220		-
221		-	(iii) what, if any, other State laws should be amended; 20
222		-
223		-	(5) review the costs associated with pharmacies contracting with 21
224		-	commercial plans versus pharmacies contracting with the Maryland Medical Assistance 22
225		-	Program; 23
226		-
227		-	(6) review provisions of State law regarding pharmacy benefit managers, 24
228		-	specialty pharmacies, and anti–steering, including: 25
229		-
230		-	(i) § 15–1611.1 of the Insurance Article related to the use of specific 26
231		-	pharmacies or entities and the effect the section has on pharmacy costs in the fully insured 27
232		-	market; and 28
233		-
234		-	(ii) § 15–1612 of the Insurance Article related to reimbursement and 29
235		-	the effect the section has on pharmacy costs in the fully insured market; 30
236		-
237		-	(5) (7) on or before December 31, 2025, submit an interim report on their 31
238		-	findings and recommendations to the Senate Finance Committee and the House Health 32 6 HOUSE BILL 813
239		-
240		-
241		-	and Government Operations Committee, in accordance with § 2 –1257 of the State 1
242		-	Government Article; and 2
243		-
244		-	(6) (8) on or before December 31, 2026, submit a final report on their findings 3
245		-	and recommendations to the Senate Finance Comm ittee and the House Health and 4
246		-	Government Operations Committee, in accordance with § 2–1257 of the State Government 5
247		-	Article. 6
248		-
249		-	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June 7
250		-	1, 2025. 8
	218	+	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June 17
	219	+	1, 2025. 18
251	220
252	221
253	222
254	223
255	224		Approved:
256	225		________________________________________________________________________________
257	226		Governor.
258	227		________________________________________________________________________________
259	228		Speaker of the House of Delegates.
260	229		________________________________________________________________________________
261	230		President of the Senate.